On Black Friday, the FDA Rules on a Disease That Has Never Had a Drug

On November 27 — Black Friday, while most of America is fighting over televisions — the FDA will decide whether to approve the first drug in history for any form of limb-girdle muscular dystrophy. The company waiting on the answer is BridgeBio Pharma (NASDAQ: BBIO), and the drug is BBP-418, an oral therapy for a subtype called LGMD2I/R9 that affects roughly 7,000 people across the United States and Europe.

If that were the whole story, it would be a footnote on the biotech calendar. It isn't. The November 27 decision is the first of three FDA verdicts BridgeBio faces in seven months, each one a potential first-ever approval for a disease that has no therapy of its own. For a company that was left for dead five years ago, it is the beginning of the most consequential stretch in its history.

The Walk Test That Almost Killed the Company

On December 27, 2021, BridgeBio announced that its lead drug, acoramidis, had missed the primary endpoint in the first part of its pivotal heart-disease trial. Patients on the drug declined by nine meters on a six-minute walk test; patients on placebo declined by seven. The stock closed down 72% that day, at $11.38.

The miss turned out to be a statistical head fake — the placebo group in that trial held up unusually well at the 12-month mark, performing more like healthy elderly adults than untreated patients. The longer 30-month readout of the same study showed what the drug actually did: significant reductions in cardiovascular death and cardiovascular-related hospitalization, the basis on which the FDA approved it — as Attruby, for transthyretin amyloid cardiomyopathy (ATTR-CM) — on November 22, 2024.

Two years into launch, Attruby did $253.2 million in U.S. net revenue in the third quarter of 2026 alone — up roughly $145 million, or about 134%, from a year earlier, and growing $31 million sequentially. That is a $1 billion annualized run rate, built inside one of the most competitive rare-disease markets in the world, against Pfizer's incumbent franchise and Alnylam's silencers. BridgeBio shares traded near $76 on Thursday, about 6.7 times that December 2021 close, giving the company a market value of roughly $14.8 billion on 194.8 million shares.

The comeback is already priced. The question is what comes next — and next is November 27.

A Disease That Only Gets Worse

LGMD2I/R9 is a genetic disease. Mutations in the FKRP gene impair the glycosylation of a protein called alpha-dystroglycan, which anchors muscle fibers to the matrix around them. Without that anchor, muscle tears itself apart with use. Onset typically comes in late childhood; in adulthood, 25% of patients lose the ability to walk independently, 10% need assisted ventilation, and 30% develop cardiomyopathy, losing heart-pumping function at a measurable rate every year. There is no approved treatment — not for this subtype, and not for any other form of limb-girdle muscular dystrophy.

BBP-418 is an oral small molecule, a glycosylation substrate: it floods the impaired enzymatic pathway with raw material so the defective enzyme can still do its job. In BridgeBio's Phase 3 FORTIFY trial, that mechanism translated into numbers rare-disease investors almost never see:

• Glycosylated alpha-dystroglycan increased 1.8x from baseline at three months (p<0.0001), sustained at twelve months — restored, in later analyses, to the levels of asymptomatic carriers.
• Serum creatine kinase, a marker of ongoing muscle destruction, fell 82% (p<0.0001).
• Walking speed improved — a 0.27 meters-per-second gain versus placebo on the 100-meter timed test (p<0.0001), and an improvement from baseline, not just a slower decline.
• Lung function improved by roughly 5% of predicted volume versus placebo (p=0.0071).

New cardiac data presented in October 2026 pushed the story further: among patients who started the trial with elevated troponin I — a blood marker of heart muscle injury — 100% of those on BBP-418 returned to the normal range by month twelve, versus 40% on placebo (p=0.0248).

Degenerative muscle diseases do not usually produce improvement rows in a data table. Stabilization is the standard definition of success. That is why the FDA granted Priority Review, and it is why no advisory committee has been scheduled — the agency intends to decide this one on the file.

Briefings like this are free to read with a free AlphaBriefing membership. Join free →

The science is the part everyone can read in a press release. The investment case lives in a different set of numbers: what a 7,000-patient disease is actually worth to a $14.8 billion company, how far along the launch already is before approval day, the nine-figure asset that arrives with the approval letter itself, and what happens to the stock if the FDA balks at a biomarker-led application on Black Friday.

The rest of this briefing is for paid members: the quarter that quietly moved BridgeBio to the edge of profitability, the patient-by-patient launch math already in motion — including how much of the market BridgeBio has located before approval — the $195 million precedent for the voucher this approval would mint, the February 4 and May 8 catalysts stacked behind it, and the bottom-line scenarios for both an approval and a rejection.

AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish — the analysis private intel clients pay four figures for, at a fraction of that.

Unlock the full briefing →